Agilus Diagnostics, a subsidiary of Fortis Healthcare Ltd. and one of India’s leading providers of diagnostic services, has unveiled its pioneering AgilusEDGE Comprehensive Genomic Profile (CGP) Rapid at its state-of-the-art Reference Laboratory in Gurugram. This breakthrough test represents a major milestone in cancer diagnostics, offering oncologists access to comprehensive genomic profiling of more than 500 cancer-related genes within just four working days.
Traditionally, genomic profiling for cancer patients could take up to 30 days—often delaying crucial treatment decisions. Powered by advanced next-generation sequencing (NGS) technology, the AgilusEDGE CGP Rapid slashes this timeline dramatically, delivering fast, actionable insights that enable oncologists to personalise treatment plans without delay. With this, Agilus Diagnostics becomes the first commercial laboratory in India to provide such rapid, multi-gene profiling.
On the occasion, Dr Anand K, Managing Director & CEO at Agilus Diagnostics, stated:
“By bringing down the turnaround time for comprehensive genomic profiling from nearly a month to just four working days, Agilus Diagnostics has taken a decisive leap forward in cancer care. Being the first lab chain in India to introduce this capability, we are not only redefining industry benchmarks but also ensuring that patients and oncologists have faster access to critical insights when every day matters. This breakthrough reflects our commitment to making advanced, precision diagnostics-led personalised medicine a reality for patients across India.”
Comprehensive analysis of 500+ genes associated with targeted therapies and precision oncology.
Turnaround time of 4 working days, compared to several weeks with conventional methods.
Compatibility with formalin-fixed paraffin-embedded (FFPE) tissue, ensuring seamless integration into existing diagnostic workflows.
This launch strengthens Agilus Diagnostics’ leadership in precision diagnostics, helping to close the gap between cancer diagnosis and timely treatment—ultimately improving patient outcomes across India.